|[July 29, 2014]
INVESTOR ALERT: Investigation of Galectin Therapeutics Inc. Announced by Glancy Binkow & Goldberg LLP
LOS ANGELES --(Business Wire)--
Binkow & Goldberg LLP announces that it is investigating
potential claims on behalf of investors of Galectin Therapeutics Inc.
("Galectin" or the "Company") (NASDAQ:GALT) concerning possible
violations of federal securities laws. The investigation focuses on
certain statements issued by the Company concerning Galectin's business
and financial prospects.
Please contact Casey Sadler, Esquire, at (888) 773-9224 or (310)
201-9150, or at email@example.com
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of sares purchased.
Galectin, a development stage company, is engaged in the research and
development of therapies for fibrotic disease and cancer. The
investigation relates to the publication of a July 28, 2014, article
that disclosed that the Company had hired a stock promotions firm to
tout its securities. The investigation also relates to the Company's
July 29, 2014, disclosure that its experimental drug GR-MD-02, which was
being developed for the treatment of fatty liver disease, showed little
difference from a placebo in its Phase 1 study. On this news, shares of
Galectin declined $8.84 per share, or 60.80%, to close on July 29, 2014,
at $5.70 per share, on unusually heavy volume.
If you purchased shares of Galectin, if you have information or would
like to learn more about these claims, or if you have any questions
concerning this announcement or your rights or interests with respect to
these matters, please contact Casey Sadler, Esquire, of Glancy Binkow &
Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067, by toll-free telephone at (888) 773-9224 or by
telephone at (310) 201-9150, by e-mail to firstname.lastname@example.org,
or visit our website at http://www.glancylaw.com.
If you inquire by email, please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
[ Back To TMCnet.com's Homepage ]